CleftGeneDB-Search

Gene: TGFA

Basic information

Tag	Content
Uniprot ID	P01135; A8K286; Q15577; Q53SK7; Q9BS56; Q9UEI3; Q9UKM1; Q9UKM2; Q9UKM3;
Entrez ID	7039
Genbank protein ID	AAF13491.1; BAF82840.1; AAY14705.1; AAF05089.1; AAP35479.1; AAA52530.1; AAF05090.1; AAF05091.1; CAA49806.1; EAW99810.1; AAY14793.1; AAD12238.1; AAP97822.2; AAH05308.1; EAW99812.1; AAA61157.1; AAA61159.1;
Genbank nucleotide ID	NM_001308158.1; NM_001308159.1; NM_003236.3; NM_001099691.2;
Ensembl protein ID	ENSP00000404099; ENSP00000387493; ENSP00000295400;
Ensembl nucleotide ID	ENSG00000163235
Gene name	Protransforming growth factor alpha
Gene symbol	TGFA
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type	CPO,CL/P
Developmental stage
Data sources	Manually collected
Reference	23940636; 1361101; 1673285; 14981713; 14755461; 1352354; 19444471; 10918043; 25191068; 9345615; 16953426; 26605011; 23029012; 24805869; 7825598; 2570526; 9684776;
Functional description	TGF alpha is a mitogenic polypeptide that is able to bind to the EGF receptor/EGFR and to act synergistically with TGF beta to promote anchorage-independent cell proliferation in soft agar.
Sequence	MVPSAGQLAL FALGIVLAAC QALENSTSPL SADPPVAAAV VSHFNDCPDS HTQFCFHGTC 60 RFLVQEDKPA CVCHSGYVGA RCEHADLLAV VAASQKKQAI TALVVVSIVA LAVLIITCVL 120 IHCCQVRKHC EWCRALICRH EKPSALLKGR TACCHSETVV

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1GK5
1MOX
1YUF
1YUG
2TGF
3E50
3TGF
4TGF
5KN5
1MOX
1YUF

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	TGFA	7039	P01135	CPO,CL/P	Homo sapiens	Publication	More>>
1:1 ortholog	Tgfa	21802	P48030		Mus musculus	Prediction	More>>
1:1 ortholog	TGFA		H2QI26		Pan troglodytes	Prediction	More>>
1:1 ortholog	TGFA		F1SLD3		Sus scrofa	Prediction	More>>
1:1 ortholog	Tgfa	24827	P01134		Rattus norvegicus	Prediction	More>>
1:1 ortholog	tgfa		I3ISP4		Danio rerio	Prediction	More>>

Identified variants/mutations related to cleft phenotype

Gene symbol	Significant Variants/SNPS	Methods	PubMed ID
TGFA	rs11466297A> C	Genotyping;PCR-RFLP	26605011
TGFA	rs3771497T>G	Genotyping; TDT	24805869
TGFA	rs3821261T>G	Genotyping;TDT	19444471
TGFA	rs3771475A>G	Genotyping;TDT	19444471
TGFA	rs2902345	TaqMan	23029012
TGFA	rs3771494T>C	PCR	23940636
TGFA	rs3771523G>A; c.3822G>A	PCR	23940636
TGFA	rs11466285T>C; c.3851T>C	PCR	23940636
TGFA	rs7605323T>C	Genotyping	21462296

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs782335405	p.Val2Phe	missense variant	-	NC_000002.12:g.70553764C>A	ExAC,TOPMed,gnomAD
rs782335405	p.Val2Ile	missense variant	-	NC_000002.12:g.70553764C>T	ExAC,TOPMed,gnomAD
rs1553507222	p.Pro3Ala	missense variant	-	NC_000002.12:g.70553761G>C	gnomAD
rs782230526	p.Pro3His	missense variant	-	NC_000002.12:g.70553760G>T	ExAC,TOPMed,gnomAD
rs782230526	p.Pro3Leu	missense variant	-	NC_000002.12:g.70553760G>A	ExAC,TOPMed,gnomAD
rs199781024	p.Ser4Trp	missense variant	-	NC_000002.12:g.70553757G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs781918389	p.Ser4Ala	missense variant	-	NC_000002.12:g.70553758A>C	ExAC,TOPMed,gnomAD
rs199781024	p.Ser4Leu	missense variant	-	NC_000002.12:g.70553757G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs199781024	p.Ser4Ter	stop gained	-	NC_000002.12:g.70553757G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs868956335	p.Gly6Ter	stop gained	-	NC_000002.12:g.70553752C>A	TOPMed
rs1553507217	p.Gly6Glu	missense variant	-	NC_000002.12:g.70553751C>T	gnomAD
rs868956335	p.Gly6Arg	missense variant	-	NC_000002.12:g.70553752C>T	TOPMed
rs1226184340	p.Gln7Arg	missense variant	-	NC_000002.12:g.70553748T>C	TOPMed
rs782692803	p.Leu8Phe	missense variant	-	NC_000002.12:g.70553746G>A	ExAC,TOPMed,gnomAD
rs572189928	p.Leu8Arg	missense variant	-	NC_000002.12:g.70553745A>C	1000Genomes,ExAC,TOPMed,gnomAD
rs1206935435	p.Ala9Val	missense variant	-	NC_000002.12:g.70553742G>A	TOPMed,gnomAD
rs782496378	p.Phe11Leu	missense variant	-	NC_000002.12:g.70553735G>T	ExAC,gnomAD
rs1553507213	p.Ala12Ser	missense variant	-	NC_000002.12:g.70553734C>A	gnomAD
rs1553501402	p.Ile15Asn	missense variant	-	NC_000002.12:g.70514909A>T	gnomAD
rs782074408	p.Ala19Val	missense variant	-	NC_000002.12:g.70514897G>A	ExAC,TOPMed,gnomAD
rs1336263613	p.Ala19Ser	missense variant	-	NC_000002.12:g.70514898C>A	TOPMed
COSM3407951	p.Gln21Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000002.12:g.70514891T>C	NCI-TCGA Cosmic
rs10183171	p.Gln21His	missense variant	-	NC_000002.12:g.70514890C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1553501396	p.Glu24Ala	missense variant	-	NC_000002.12:g.70514882T>G	gnomAD
COSM443147	p.Asn25Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000002.12:g.70514880T>C	NCI-TCGA Cosmic
rs200477881	p.Asn25Lys	missense variant	-	NC_000002.12:g.70514878G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs200477881	p.Asn25Lys	missense variant	-	NC_000002.12:g.70514878G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs138392270	p.Thr27Lys	missense variant	-	NC_000002.12:g.70514873G>T	ESP,ExAC,TOPMed,gnomAD
rs138392270	p.Thr27Met	missense variant	-	NC_000002.12:g.70514873G>A	ESP,ExAC,TOPMed,gnomAD
COSM4934403	p.Ser28Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000002.12:g.70514870G>C	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ser28Phe	missense variant	-	NC_000002.12:g.70514870G>A	NCI-TCGA
rs1476246950	p.Ser28Thr	missense variant	-	NC_000002.12:g.70514871A>T	TOPMed,gnomAD
rs370723372	p.Pro29Leu	missense variant	-	NC_000002.12:g.70514867G>A	ESP,ExAC,TOPMed,gnomAD
rs1156844341	p.Pro29Ser	missense variant	-	NC_000002.12:g.70514868G>A	TOPMed
rs782632960	p.Ser31Asn	missense variant	-	NC_000002.12:g.70514861C>T	ExAC,gnomAD
rs782601026	p.Ala32Glu	missense variant	-	NC_000002.12:g.70465736G>T	ExAC,TOPMed,gnomAD
rs1373383061	p.Ala32Thr	missense variant	-	NC_000002.12:g.70514859C>T	TOPMed
rs199569305	p.Pro34Leu	missense variant	-	NC_000002.12:g.70465730G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs147786817	p.Val36Met	missense variant	-	NC_000002.12:g.70465725C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs922910710	p.Ala38Thr	missense variant	-	NC_000002.12:g.70465719C>T	gnomAD
rs199700477	p.Ala38Glu	missense variant	-	NC_000002.12:g.70465718G>T	1000Genomes,ExAC,TOPMed,gnomAD
rs373378868	p.Ala39Val	missense variant	-	NC_000002.12:g.70465715G>A	ESP,ExAC,TOPMed,gnomAD
rs782683659	p.Val40Ala	missense variant	-	NC_000002.12:g.70465712A>G	ExAC,gnomAD
rs782012686	p.Ser42Thr	missense variant	-	NC_000002.12:g.70465707A>T	ExAC,TOPMed,gnomAD
rs782818852	p.His43Leu	missense variant	-	NC_000002.12:g.70465703T>A	ExAC,gnomAD
rs782112864	p.Asn45Ser	missense variant	-	NC_000002.12:g.70465697T>C	ExAC,gnomAD
NCI-TCGA novel	p.Asp49Asn	missense variant	-	NC_000002.12:g.70465686C>T	NCI-TCGA
rs1553492087	p.Ser50Phe	missense variant	-	NC_000002.12:g.70465682G>A	gnomAD
rs1553492083	p.Gln53Arg	missense variant	-	NC_000002.12:g.70465673T>C	TOPMed,gnomAD
rs943061798	p.Gln53His	missense variant	-	NC_000002.12:g.70465672C>G	gnomAD
rs1448049520	p.His57Gln	missense variant	-	NC_000002.12:g.70465660A>T	TOPMed
rs1285482265	p.Gly58Val	missense variant	-	NC_000002.12:g.70465658C>A	TOPMed
rs781919023	p.Thr59Pro	missense variant	-	NC_000002.12:g.70465656T>G	ExAC,gnomAD
rs1553492074	p.Phe62Val	missense variant	-	NC_000002.12:g.70465647A>C	gnomAD
rs782323977	p.Val64Met	missense variant	-	NC_000002.12:g.70465641C>T	ExAC,gnomAD
rs1381914629	p.Glu66Asp	missense variant	-	NC_000002.12:g.70465633C>G	TOPMed
rs1553492070	p.Asp67Asn	missense variant	-	NC_000002.12:g.70465632C>T	gnomAD
rs782280290	p.Asp67Glu	missense variant	-	NC_000002.12:g.70465630G>C	ExAC,gnomAD
rs782280290	p.Asp67Glu	missense variant	-	NC_000002.12:g.70465630G>T	ExAC,gnomAD
rs782681901	p.Pro69Ser	missense variant	-	NC_000002.12:g.70465626G>A	ExAC,TOPMed,gnomAD
rs1553492067	p.Ala70Val	missense variant	-	NC_000002.12:g.70465622G>A	gnomAD
rs1553492059	p.Cys71Ser	missense variant	-	NC_000002.12:g.70465620A>T	gnomAD
rs1553492054	p.Val72Ile	missense variant	-	NC_000002.12:g.70465617C>T	gnomAD
rs782068767	p.His74Arg	missense variant	-	NC_000002.12:g.70456483T>C	ExAC,gnomAD
rs148679837	p.Val78Ile	missense variant	-	NC_000002.12:g.70456472C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs782244656	p.Val78Ala	missense variant	-	NC_000002.12:g.70456471A>G	ExAC,gnomAD
rs1553490570	p.Arg81His	missense variant	-	NC_000002.12:g.70456462C>T	gnomAD
rs1377948470	p.Arg81Cys	missense variant	-	NC_000002.12:g.70456463G>A	TOPMed,gnomAD
rs1418346765	p.Ala85Val	missense variant	-	NC_000002.12:g.70456450G>A	TOPMed,gnomAD
rs782577747	p.Val90Met	missense variant	-	NC_000002.12:g.70456436C>T	ExAC,TOPMed,gnomAD
rs782531188	p.Val91Met	missense variant	-	NC_000002.12:g.70456433C>T	ExAC,gnomAD
rs1553490560	p.Ala93Thr	missense variant	-	NC_000002.12:g.70456427C>T	gnomAD
rs539481707	p.Lys97Gln	missense variant	-	NC_000002.12:g.70456415T>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1553490554	p.Ala99Thr	missense variant	-	NC_000002.12:g.70456409C>T	gnomAD
rs1553490550	p.Ala99Asp	missense variant	-	NC_000002.12:g.70456408G>T	gnomAD
rs1553490548	p.Ile100Thr	missense variant	-	NC_000002.12:g.70456405A>G	gnomAD
rs373035967	p.Thr101Ser	missense variant	-	NC_000002.12:g.70456402G>C	ESP,ExAC,TOPMed,gnomAD
rs781983111	p.Thr101Ala	missense variant	-	NC_000002.12:g.70456403T>C	TOPMed,gnomAD
rs373035967	p.Thr101Asn	missense variant	-	NC_000002.12:g.70456402G>T	ESP,ExAC,TOPMed,gnomAD
rs570448487	p.Ala102Thr	missense variant	-	NC_000002.12:g.70456400C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs1553490542	p.Leu103Phe	missense variant	-	NC_000002.12:g.70456395C>G	gnomAD
rs1553490544	p.Leu103Trp	missense variant	-	NC_000002.12:g.70456396A>C	gnomAD
rs527352558	p.Val105Met	missense variant	-	NC_000002.12:g.70456391C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs527352558	p.Val105Leu	missense variant	-	NC_000002.12:g.70456391C>A	1000Genomes,ExAC,TOPMed,gnomAD
COSM3910524	p.Ser107Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000002.12:g.70456384G>A	NCI-TCGA Cosmic
rs1438573302	p.Ile108Val	missense variant	-	NC_000002.12:g.70456382T>C	TOPMed
rs11466259	p.Val109Met	missense variant	-	NC_000002.12:g.70456379C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs11466259	p.Val109Met	missense variant	-	NC_000002.12:g.70456379C>T	UniProt,dbSNP
VAR_024271	p.Val109Met	missense variant	-	NC_000002.12:g.70456379C>T	UniProt
rs1553490529	p.Ala110Thr	missense variant	-	NC_000002.12:g.70456376C>T	gnomAD
rs1553490525	p.Ala112Thr	missense variant	-	NC_000002.12:g.70456370C>T	gnomAD
COSM3426636	p.Ala112Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000002.12:g.70456369G>A	NCI-TCGA Cosmic
rs782173840	p.Val113Ile	missense variant	-	NC_000002.12:g.70456367C>T	ExAC,gnomAD
rs1553490524	p.Leu114Phe	missense variant	-	NC_000002.12:g.70456364G>A	gnomAD
rs1553490518	p.Cys118Arg	missense variant	-	NC_000002.12:g.70456352A>G	gnomAD
rs1553490513	p.Ile121Met	missense variant	-	NC_000002.12:g.70456341T>C	gnomAD
rs1465708840	p.Cys123Phe	missense variant	-	NC_000002.12:g.70453325C>A	TOPMed,gnomAD
rs1191020370	p.Cys124Arg	missense variant	-	NC_000002.12:g.70453323A>G	TOPMed,gnomAD
rs1236281679	p.Cys124Phe	missense variant	-	NC_000002.12:g.70453322C>A	TOPMed
rs781896307	p.Val126Ile	missense variant	-	NC_000002.12:g.70453317C>T	gnomAD
rs781896307	p.Val126Leu	missense variant	-	NC_000002.12:g.70453317C>G	gnomAD
rs146962706	p.Arg127Gln	missense variant	-	NC_000002.12:g.70453313C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs782253342	p.Arg127Ter	stop gained	-	NC_000002.12:g.70453314G>A	ExAC,gnomAD
rs1553489984	p.His129Tyr	missense variant	-	NC_000002.12:g.70453308G>A	gnomAD
rs782356331	p.Cys130Ser	missense variant	-	NC_000002.12:g.70453304C>G	ExAC
rs1553489982	p.Cys130Arg	missense variant	-	NC_000002.12:g.70453305A>G	gnomAD
rs1553489977	p.Glu131Val	missense variant	-	NC_000002.12:g.70453301T>A	gnomAD
rs782179752	p.Glu131Lys	missense variant	-	NC_000002.12:g.70453302C>T	ExAC,gnomAD
rs1553489976	p.Trp132Ter	stop gained	-	NC_000002.12:g.70453298C>T	gnomAD
NCI-TCGA novel	p.Trp132Ter	stop gained	-	NC_000002.12:g.70453297_70453298insAGCCTTAGCTGTCTTGAAGAGGCCAGACATTT	NCI-TCGA
rs372158742	p.Arg134Gln	missense variant	-	NC_000002.12:g.70453292C>T	ESP,ExAC,gnomAD
rs782586279	p.Arg134Trp	missense variant	-	NC_000002.12:g.70453293G>A	ExAC,TOPMed,gnomAD
rs200451222	p.Leu136His	missense variant	-	NC_000002.12:g.70453286A>T	TOPMed
rs1416150018	p.Leu136Phe	missense variant	-	NC_000002.12:g.70453287G>A	TOPMed
rs781911960	p.Ile137Met	missense variant	-	NC_000002.12:g.70453282G>C	ExAC,gnomAD
rs554966762	p.Arg139Gln	missense variant	-	NC_000002.12:g.70453277C>T	ExAC,TOPMed,gnomAD
rs554966762	p.Arg139Pro	missense variant	-	NC_000002.12:g.70453277C>G	ExAC,TOPMed,gnomAD
rs147241222	p.Arg139Trp	missense variant	-	NC_000002.12:g.70453278G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.His140Tyr	missense variant	-	NC_000002.12:g.70453275G>A	NCI-TCGA
NCI-TCGA novel	p.His140Arg	missense variant	-	NC_000002.12:g.70453274T>C	NCI-TCGA
rs781826380	p.Glu141Lys	missense variant	-	NC_000002.12:g.70453272C>T	ExAC,TOPMed,gnomAD
rs782700834	p.Glu141Ala	missense variant	-	NC_000002.12:g.70453271T>G	ExAC,gnomAD
rs781826380	p.Glu141Gln	missense variant	-	NC_000002.12:g.70453272C>G	ExAC,TOPMed,gnomAD
rs782058394	p.Ser144Arg	missense variant	-	NC_000002.12:g.70453261G>T	ExAC,TOPMed,gnomAD
rs782808061	p.Ala145Gly	missense variant	-	NC_000002.12:g.70453259G>C	ExAC,gnomAD
rs535108529	p.Ala145Thr	missense variant	-	NC_000002.12:g.70453260C>T	ExAC,TOPMed,gnomAD
rs1348188205	p.Leu146Val	missense variant	-	NC_000002.12:g.70453257G>C	TOPMed
COSM3582796	p.Leu146Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000002.12:g.70453257G>A	NCI-TCGA Cosmic
rs1227430130	p.Leu147Gln	missense variant	-	NC_000002.12:g.70453253A>T	TOPMed
rs782115973	p.Gly149Glu	missense variant	-	NC_000002.12:g.70453247C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly149Ala	missense variant	-	NC_000002.12:g.70453247C>G	NCI-TCGA
rs782001599	p.Arg150Thr	missense variant	-	NC_000002.12:g.70453244C>G	ExAC,gnomAD
rs1553489950	p.Arg150Ser	missense variant	-	NC_000002.12:g.70453243T>G	gnomAD
rs782326575	p.Ala152Asp	missense variant	-	NC_000002.12:g.70453238G>T	ExAC,gnomAD
rs782095962	p.Ala152Thr	missense variant	-	NC_000002.12:g.70453239C>T	ExAC,TOPMed,gnomAD
rs782326575	p.Ala152Val	missense variant	-	NC_000002.12:g.70453238G>A	ExAC,gnomAD
rs199594512	p.Cys153Ter	stop gained	-	NC_000002.12:g.70453234G>T	ExAC,gnomAD
rs1211195333	p.Cys153Tyr	missense variant	-	NC_000002.12:g.70453235C>T	TOPMed
rs782687296	p.Ser156Leu	missense variant	-	NC_000002.12:g.70453226G>A	ExAC,TOPMed,gnomAD
rs1181697045	p.Thr158Pro	missense variant	-	NC_000002.12:g.70453221T>G	TOPMed
rs1553489514	p.Val159Ala	missense variant	-	NC_000002.12:g.70450866A>G	gnomAD
rs377029144	p.Val160Ile	missense variant	-	NC_000002.12:g.70450864C>T	ESP,ExAC,gnomAD
NCI-TCGA novel	p.Ter161TrpGluUnkThrTerUnkUnk	stop lost	-	NC_000002.12:g.70450859T>C	NCI-TCGA

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0000768	Congenital Abnormality	group	BEFREE
C0000846	Agenesis	disease	BEFREE
C0001418	Adenocarcinoma	group	BEFREE;LHGDN
C0001430	Adenoma	group	BEFREE
C0002793	Anaplasia	disease	BEFREE
C0002893	Refractory anemias	disease	BEFREE
C0002940	Aneurysm	phenotype	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0004096	Asthma	disease	BEFREE
C0004114	Astrocytoma	disease	BEFREE
C0004623	Bacterial Infections	group	BEFREE
C0006118	Brain Neoplasms	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0006145	Breast Diseases	group	BEFREE
C0006287	Bronchopulmonary Dysplasia	disease	BEFREE
C0006413	Burkitt Lymphoma	disease	BEFREE
C0006625	Cachexia	phenotype	BEFREE
C0006840	Candidiasis	disease	BEFREE
C0007095	Carcinoid Tumor	group	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007103	Malignant neoplasm of endometrium	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE;CTD_human
C0007133	Carcinoma, Papillary	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE;LHGDN
C0007138	Carcinoma, Transitional Cell	disease	BEFREE
C0007570	Celiac Disease	disease	BEFREE
C0008497	Choriocarcinoma	disease	BEFREE
C0008924	Cleft upper lip	disease	BEFREE
C0008925	Cleft Palate	disease	BEFREE;LHGDN
C0009324	Ulcerative Colitis	disease	BEFREE
C0009375	Colonic Neoplasms	group	LHGDN
C0009402	Colorectal Carcinoma	disease	BEFREE
C0009404	Colorectal Neoplasms	group	BEFREE
C0011881	Diabetic Nephropathy	disease	BEFREE
C0013264	Muscular Dystrophy, Duchenne	disease	BEFREE
C0013312	Dupuytren Contracture	disease	BEFREE
C0016045	fibroma	disease	BEFREE
C0017154	Gastritis, Atrophic	disease	BEFREE;LHGDN
C0017155	Gastritis, Hypertrophic	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0017661	IGA Glomerulonephritis	disease	BEFREE
C0018206	granulosa cell tumor	disease	BEFREE
C0018671	Head and Neck Neoplasms	group	BEFREE;CTD_human
C0018675	Head Neoplasms	group	CTD_human
C0019158	Hepatitis	disease	BEFREE
C0019159	Hepatitis A	disease	BEFREE
C0019163	Hepatitis B	disease	BEFREE;LHGDN
C0019189	Hepatitis, Chronic	disease	BEFREE
C0019196	Hepatitis C	disease	BEFREE
C0019207	Hepatoma, Morris	disease	CTD_human
C0019208	Hepatoma, Novikoff	disease	CTD_human
C0019562	Von Hippel-Lindau Syndrome	disease	BEFREE
C0020503	Hyperparathyroidism, Secondary	disease	BEFREE
C0020507	Hyperplasia	phenotype	LHGDN
C0020538	Hypertensive disease	group	BEFREE
C0020542	Pulmonary Hypertension	phenotype	CTD_human;LHGDN
C0020608	Hypodontia	disease	ORPHANET
C0021368	Inflammation	phenotype	CTD_human
C0021390	Inflammatory Bowel Diseases	group	BEFREE
C0022354	Jaundice, Obstructive	disease	BEFREE
C0022658	Kidney Diseases	group	BEFREE
C0022660	Kidney Failure, Acute	disease	RGD
C0022665	Kidney Neoplasm	disease	BEFREE
C0022680	Polycystic Kidney Diseases	group	BEFREE
C0023051	Laryngeal Diseases	group	BEFREE
C0023418	leukemia	disease	BEFREE
C0023487	Acute Promyelocytic Leukemia	disease	BEFREE
C0023890	Liver Cirrhosis	disease	BEFREE;LHGDN
C0023896	Alcoholic Liver Diseases	group	BEFREE
C0023903	Liver neoplasms	group	BEFREE;CTD_human
C0023904	Liver Neoplasms, Experimental	group	CTD_human
C0024115	Lung diseases	group	BEFREE
C0024121	Lung Neoplasms	group	LHGDN
C0024623	Malignant neoplasm of stomach	disease	BEFREE;CTD_human
C0024667	Animal Mammary Neoplasms	group	CTD_human
C0024668	Mammary Neoplasms, Experimental	group	CTD_human
C0025202	melanoma	disease	BEFREE
C0025286	Meningioma	disease	BEFREE
C0025500	Mesothelioma	disease	BEFREE
C0025990	Micrognathism	disease	HPO
C0027533	Neck Neoplasms	group	CTD_human
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0027708	Nephroblastoma	disease	BEFREE
C0027746	Nerve Degeneration	phenotype	CTD_human
C0027819	Neuroblastoma	group	BEFREE
C0027830	neurofibroma	disease	BEFREE
C0028754	Obesity	disease	BEFREE
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030246	Pustulosis of Palms and Soles	disease	CTD_human
C0030297	Pancreatic Neoplasm	disease	BEFREE;RGD
C0030354	Papilloma	disease	BEFREE;CTD_human
C0031511	Pheochromocytoma	disease	BEFREE
C0032000	Pituitary Adenoma	disease	BEFREE
C0032285	Pneumonia	disease	BEFREE
C0032927	Precancerous Conditions	group	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE;CTD_human
C0033860	Psoriasis	disease	BEFREE;CTD_human
C0034013	Precocious Puberty	disease	BEFREE
C0034063	Pulmonary Edema	disease	CTD_human
C0034067	Pulmonary Emphysema	disease	BEFREE
C0034069	Pulmonary Fibrosis	disease	BEFREE;CTD_human
C0038356	Stomach Neoplasms	group	BEFREE;CTD_human
C0041207	Truncus Arteriosus, Persistent	disease	BEFREE
C0042373	Vascular Diseases	group	BEFREE
C0042769	Virus Diseases	group	BEFREE
C0079218	Fibromatosis, Aggressive	disease	BEFREE
C0085413	Polycystic Kidney, Autosomal Dominant	disease	BEFREE
C0085786	Hamman-Rich syndrome	disease	BEFREE;CTD_human
C0086404	Experimental Hepatoma	disease	CTD_human
C0086942	Rous Sarcoma	disease	BEFREE
C0149516	Chronic sinusitis	disease	BEFREE
C0149521	Pancreatitis, Chronic	disease	BEFREE
C0151779	Cutaneous Melanoma	disease	BEFREE
C0151798	Hepatic necrosis	phenotype	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152018	Esophageal carcinoma	disease	BEFREE
C0153381	Malignant neoplasm of mouth	disease	BEFREE
C0153458	malignant neoplasm of head of pancreas	disease	RGD
C0153459	Malignant neoplasm of body of pancreas	disease	RGD
C0153460	Malignant neoplasm of tail of pancreas	disease	RGD
C0153463	Malignant neoplasm of other specified sites of pancreas	disease	RGD
C0153690	Secondary malignant neoplasm of bone	disease	BEFREE
C0158646	Cleft palate with cleft lip	disease	BEFREE
C0162678	Neurofibromatoses	group	BEFREE
C0162770	Right Ventricular Hypertrophy	disease	CTD_human
C0162869	Aneurysm, Ruptured	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0205748	Dysplastic Nevus	disease	BEFREE
C0205874	Papilloma, Squamous Cell	disease	CTD_human
C0205875	Papillomatosis	disease	CTD_human
C0206062	Lung Diseases, Interstitial	group	BEFREE
C0206141	Idiopathic Hypereosinophilic Syndrome	disease	BEFREE
C0206624	Hepatoblastoma	disease	BEFREE;CTD_human
C0206664	Teratocarcinoma	disease	BEFREE
C0206706	Verrucous carcinoma	disease	LHGDN
C0206727	Nerve Sheath Tumors	group	BEFREE
C0206734	Hemangioblastoma	disease	BEFREE
C0206754	Neuroendocrine Tumors	group	BEFREE
C0220620	Gastrointestinal Carcinoid Tumor	disease	BEFREE
C0220641	Lip and Oral Cavity Carcinoma	disease	BEFREE
C0220650	Metastatic malignant neoplasm to brain	disease	BEFREE
C0220810	Congenital defects	group	BEFREE
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238462	Medullary carcinoma of thyroid	disease	BEFREE
C0238463	Papillary thyroid carcinoma	disease	BEFREE
C0239946	Fibrosis, Liver	disease	BEFREE
C0240310	Hypoplasia of the maxilla	disease	HPO
C0240340	Microdontia (disorder)	disease	HPO
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0243038	Carcinoma, Lewis Lung	disease	BEFREE
C0263454	Chloracne	disease	BEFREE
C0263641	Epithelial hyperplasia of skin	disease	BEFREE
C0263662	Disseminated eosinophilic collagen disease	disease	BEFREE
C0264545	Thickening of pleura	disease	BEFREE
C0267797	Acute hepatitis	disease	BEFREE
C0267952	Fibrosis of pancreas	disease	BEFREE
C0268398	Familial lichen amyloidosis	disease	BEFREE
C0268621	Hepatic methionine adenosyltransferase deficiency	disease	BEFREE
C0271527	Cryptogenic sexual precocity	phenotype	BEFREE
C0271844	Parathyroid hyperplasia	disease	BEFREE
C0273115	Lung Injury	disease	CTD_human
C0276623	Chronic viral hepatitis	disease	BEFREE
C0278504	Non-small cell lung cancer stage I	disease	BEFREE
C0278601	Inflammatory Breast Carcinoma	disease	BEFREE
C0278688	Stage IV Ovarian Carcinoma	disease	BEFREE
C0278996	Malignant Head and Neck Neoplasm	disease	BEFREE;CTD_human
C0279000	Liver and Intrahepatic Biliary Tract Carcinoma	disease	BEFREE
C0279607	Adult Hepatocellular Carcinoma	disease	RGD
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0279702	Conventional (Clear Cell) Renal Cell Carcinoma	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0333355	Inflammatory disease of mucous membrane	group	CTD_human
C0334299	Carcinoid tumor no ICD-O subtype	phenotype	BEFREE
C0338106	Adenocarcinoma of colon	disease	BEFREE
C0341439	Chronic liver disease	group	BEFREE
C0345893	Juvenile polyposis syndrome	disease	BEFREE
C0345904	Malignant neoplasm of liver	disease	BEFREE;CTD_human
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE;CTD_human
C0376544	Hematopoietic Neoplasms	group	BEFREE
C0399352	Developmental absence of tooth	disease	BEFREE
C0399474	Dysplastic oral leukoplakia	disease	BEFREE
C0406317	Chronic small plaque psoriasis	disease	BEFREE
C0409959	Osteoarthritis, Knee	disease	BEFREE
C0476089	Endometrial Carcinoma	disease	BEFREE
C0524909	Hepatitis B, Chronic	disease	BEFREE
C0524910	Hepatitis C, Chronic	disease	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0555198	Malignant Glioma	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0595989	Carcinoma of larynx	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598935	Tumor Initiation	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0677932	Progressive Neoplastic Disease	phenotype	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0685938	Malignant neoplasm of gastrointestinal tract	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0699949	airway disease	group	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0740457	Malignant neoplasm of kidney	disease	BEFREE
C0746787	Cancer of Neck	disease	CTD_human
C0747845	early pregnancy	phenotype	BEFREE
C0751177	Cancer of Head	disease	CTD_human
C0751690	Malignant Peripheral Nerve Sheath Tumor	disease	BEFREE
C0810364	Cleft Lip with or without Cleft Palate	disease	BEFREE
C0850639	premalignant lesion	phenotype	BEFREE
C0850666	Infection caused by Helicobacter pylori	disease	BEFREE
C0853879	Invasive carcinoma of breast	disease	BEFREE
C0879615	Stromal Neoplasm	disease	BEFREE
C0887900	Upper Aerodigestive Tract Neoplasms	group	CTD_human
C0919267	ovarian neoplasm	disease	BEFREE
C0948380	Colorectal cancer metastatic	disease	BEFREE
C0949541	Hurthle Cell Tumor	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1153706	Endometrial adenocarcinoma	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1176475	Ductal Carcinoma	disease	BEFREE
C1257925	Mammary Carcinoma, Animal	disease	CTD_human
C1260325	Dendritic Cell Sarcoma, Follicular	disease	BEFREE
C1261473	Sarcoma	group	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1319315	Adenocarcinoma of large intestine	disease	BEFREE
C1335302	Pancreatic Ductal Adenocarcinoma	disease	BEFREE
C1368683	Epithelioma	disease	BEFREE
C1378703	Renal carcinoma	disease	BEFREE
C1402291	Pigmented lesions	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;LHGDN
C1512409	Hepatocarcinogenesis	disease	BEFREE
C1512981	Mammary Tumorigenesis	phenotype	BEFREE
C1519346	Skin Carcinogenesis	disease	BEFREE
C1519670	Tumor Angiogenesis	phenotype	BEFREE
C1519689	Tumor Promotion	phenotype	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1527349	Ductal Breast Carcinoma	disease	BEFREE
C1535510	ADENOMAS AND ADENOCARCINOMAS	group	BEFREE
C1540912	Hypereosinophilic syndrome	disease	BEFREE
C1561643	Chronic Kidney Diseases	group	BEFREE
C1562312	Estrogen receptor positive tumor	disease	BEFREE
C1567435	Polycystic Kidney - body part	phenotype	BEFREE
C1623038	Cirrhosis	disease	BEFREE
C1704272	Benign Prostatic Hyperplasia	disease	BEFREE
C1708349	Hereditary Diffuse Gastric Cancer	disease	CTD_human
C1737329	Dysmorphism	disease	BEFREE
C1800706	Idiopathic Pulmonary Fibrosis	disease	BEFREE
C1833921	Familial medullary thyroid carcinoma	disease	BEFREE
C1833929	THYROID CARCINOMA, SPORADIC MEDULLARY	disease	BEFREE
C1837218	Cleft palate, isolated	disease	BEFREE
C1857130	Hypoplastic mandible condyle	phenotype	HPO
C1861537	OROFACIAL CLEFT 1	disease	BEFREE
C1883486	Uterine Corpus Cancer	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE;CTD_human;LHGDN
C2350344	Chronic Lung Injury	disease	CTD_human
C2711227	Steatohepatitis	disease	BEFREE
C2720436	Fibrosis of pleura	disease	BEFREE
C2745900	Promyelocytic leukemia	disease	BEFREE
C2931852	Clear-cell metastatic renal cell carcinoma	disease	BEFREE
C2981150	Uranostaphyloschisis	disease	BEFREE
C3489791	Parkinson Disease, Familial, Type 1	disease	BEFREE
C3539781	Progressive cGVHD	disease	BEFREE
C3539878	Triple Negative Breast Neoplasms	disease	BEFREE
C3658266	Prostatic Cancer, Castration-Resistant	disease	BEFREE
C3711374	Nonsyndromic Deafness	disease	CTD_human
C3714636	Pneumonitis	disease	BEFREE
C3893645	response to ACE inhibitor	phenotype	GWASCAT
C4024589	Aplasia/Hypoplasia of the mandible	phenotype	HPO
C4048328	cervical cancer	disease	BEFREE
C4082243	Maxillary retrognathia	phenotype	HPO
C4082304	Oligodontia	disease	HPO;ORPHANET
C4085370	Fibromatosis, Palmar	disease	BEFREE
C4280611	Decreased size of teeth	phenotype	HPO
C4280612	Decreased width of tooth	phenotype	HPO
C4280619	Missing more than six teeth	phenotype	HPO
C4280640	Retrusion of upper jaw bones	phenotype	HPO
C4280641	Hypotrophic maxilla	phenotype	HPO
C4280642	Deficiency of upper jaw bones	phenotype	HPO
C4280643	Decreased projection of maxilla	phenotype	HPO
C4321245	Cleft lip or lips	phenotype	BEFREE
C4476523	Decreased projection of lower jaw	phenotype	HPO
C4476524	Decreased projection of mandible	phenotype	HPO
C4476525	Retrusion of lower jaw	phenotype	HPO

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0005154	epidermal growth factor receptor binding	IDA
GO:0005154	epidermal growth factor receptor binding	IBA
GO:0005515	protein binding	IPI
GO:0008083	growth factor activity	IDA
GO:0008083	growth factor activity	IBA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000165	MAPK cascade	TAS
GO:0000187	activation of MAPK activity	IDA
GO:0000187	activation of MAPK activity	IBA
GO:0006357	regulation of transcription by RNA polymerase II	TAS
GO:0006888	endoplasmic reticulum to Golgi vesicle-mediated transport	TAS
GO:0007165	signal transduction	TAS
GO:0007173	epidermal growth factor receptor signaling pathway	IBA
GO:0007173	epidermal growth factor receptor signaling pathway	TAS
GO:0008284	positive regulation of cell population proliferation	IBA
GO:0035556	intracellular signal transduction	TAS
GO:0042059	negative regulation of epidermal growth factor receptor signaling pathway	TAS
GO:0045741	positive regulation of epidermal growth factor-activated receptor activity	IDA
GO:0045840	positive regulation of mitotic nuclear division	IDA
GO:0048208	COPII vesicle coating	TAS
GO:0050679	positive regulation of epithelial cell proliferation	IDA
GO:0051781	positive regulation of cell division	IEA
GO:0051897	positive regulation of protein kinase B signaling	TAS
GO:0061024	membrane organization	TAS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0000139	Golgi membrane	IEA
GO:0005576	extracellular region	TAS
GO:0005615	extracellular space	IDA
GO:0005615	extracellular space	IBA
GO:0005789	endoplasmic reticulum membrane	TAS
GO:0005886	plasma membrane	NAS
GO:0009986	cell surface	IDA
GO:0012507	ER to Golgi transport vesicle membrane	TAS
GO:0016021	integral component of membrane	IEA
GO:0016323	basolateral plasma membrane	IDA
GO:0030665	clathrin-coated vesicle membrane	TAS
GO:0031410	cytoplasmic vesicle	IDA
GO:0033116	endoplasmic reticulum-Golgi intermediate compartment membrane	TAS
GO:0048471	perinuclear region of cytoplasm	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-1643713	Signaling by EGFR in Cancer	TAS
R-HSA-168256	Immune System	TAS
R-HSA-177929	Signaling by EGFR	TAS
R-HSA-179812	GRB2 events in EGFR signaling	TAS
R-HSA-180292	GAB1 signalosome	TAS
R-HSA-180336	SHC1 events in EGFR signaling	TAS
R-HSA-182971	EGFR downregulation	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-199977	ER to Golgi Anterograde Transport	TAS
R-HSA-199991	Membrane Trafficking	TAS
R-HSA-204005	COPII-mediated vesicle transport	TAS
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-212718	EGFR interacts with phospholipase C-gamma	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-446203	Asparagine N-linked glycosylation	TAS
R-HSA-5638302	Signaling by Overexpressed Wild-Type EGFR in Cancer	TAS
R-HSA-5638303	Inhibition of Signaling by Overexpressed EGFR	TAS
R-HSA-5653656	Vesicle-mediated transport	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-5694530	Cargo concentration in the ER	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis	TAS
R-HSA-8856828	Clathrin-mediated endocytosis	TAS
R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	TAS
R-HSA-8866910	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	TAS
R-HSA-8939211	ESR-mediated signaling	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006931	Signaling by Nuclear Receptors	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS
R-HSA-9009391	Extra-nuclear estrogen signaling	TAS
R-HSA-9018519	Estrogen-dependent gene expression	TAS
R-HSA-948021	Transport to the Golgi and subsequent modification	TAS
R-HSA-9607240	FLT3 Signaling	TAS
R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C038983	1,3-dimethylthiourea	1,3-dimethylthiourea inhibits the reaction [ELANE protein results in increased expression of TGFA protein]	17456367
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	[IL6 protein co-treated with HGF protein co-treated with TGFA protein] affects the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of CYP2B1 mRNA]	27530964
D020001	1-Butanol	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
C548651	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of TGFA mRNA	19933214
C029790	2,2',3',4,4',5-hexachlorobiphenyl	[2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TGFA mRNA	21277884
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [TGFA protein results in increased expression of FOS protein]	19749156
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [TGFA protein results in increased expression of GPER1 protein]	19749156
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	[2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TGFA mRNA	21277884
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TGFA mRNA	8603490
C017906	3-dinitrobenzene	3-dinitrobenzene results in decreased expression of TGFA mRNA	21983209; 22841810;
C091768	3'-methoxy-4'-nitroflavone	3'-methoxy-4'-nitroflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TGFA mRNA]	12668121
C090942	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Silicon Dioxide analog results in increased secretion of TGFA protein]	24844442
C065250	4-hydroxy-equilenin	4-hydroxy-equilenin results in increased expression of TGFA mRNA	20540524
C065250	4-hydroxy-equilenin	Fulvestrant inhibits the reaction [4-hydroxy-equilenin results in increased expression of TGFA mRNA]	20540524
C041594	4-nonylphenol	4-nonylphenol results in increased secretion of TGFA protein	28703301
C041594	4-nonylphenol	ADAM10 protein affects the reaction [ADAM17 protein affects the reaction [4-nonylphenol results in increased secretion of TGFA protein]]	28703301
C041594	4-nonylphenol	ADAM17 protein affects the reaction [4-nonylphenol results in increased secretion of TGFA protein]	28703301
C041594	4-nonylphenol	GW280264X inhibits the reaction [4-nonylphenol results in increased secretion of TGFA protein]	28703301
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] which results in increased expression of TGFA mRNA	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA mRNA	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased expression of TGFA protein	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of EGFR protein]	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	TGFA protein inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of RPS6 protein]	21266357
C480541	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one	21266357
C469552	A 419259	A 419259 inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein]	15342401
D000082	Acetaminophen	Acetaminophen results in increased expression of TGFA mRNA	29067470
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of TGFA mRNA]	15945272
C058956	acteoside	[acteoside co-treated with TGFA protein] results in increased expression of CXCL8 mRNA	21756928
C058956	acteoside	acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein]	21967610
C058956	acteoside	acteoside promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]	21967610
C058956	acteoside	acteoside inhibits the reaction [leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]]	21967610
C058956	acteoside	acteoside inhibits the reaction [leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]]	21967610
C058956	acteoside	acteoside inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]	21967610
C058956	acteoside	acteoside inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]	21967610
C058956	acteoside	acteoside inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein]	21967610
C058956	acteoside	acteoside inhibits the reaction [TGFA protein results in increased phosphorylation of EGFR protein]	21967610
C058956	acteoside	acteoside results in decreased susceptibility to TGFA protein	21967610
C058956	acteoside	acteoside results in increased susceptibility to TGFA protein	21967610
C058956	acteoside	[leptomycin B co-treated with TGFA protein co-treated with acteoside] affects the localization of EGFR protein modified form	21967610
C058956	acteoside	PD168393 inhibits the reaction [[TGFA protein co-treated with acteoside] results in increased expression of CXCL8 mRNA]	21967610
C058956	acteoside	[TGFA protein co-treated with acteoside] results in increased expression of CXCL8 mRNA	21967610
D000336	Aerosols	Aerosols results in decreased expression of TGFA protein	29505817
D000336	Aerosols	Aerosols results in increased expression of TGFA mRNA	29505817
D000393	Air Pollutants	Air Pollutants analog results in increased expression of TGFA mRNA	21757418
D024502	alpha-Tocopherol	alpha-Tocopherol results in decreased susceptibility to TGFA protein	7593635
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of TGFA mRNA	16483693
D000728	Androgens	TGFA protein results in increased abundance of Androgens	15353178
D039741	Antigens, Dermatophagoides	Antigens, Dermatophagoides results in increased secretion of TGFA protein	12077271
D039741	Antigens, Dermatophagoides	Dexamethasone inhibits the reaction [Antigens, Dermatophagoides results in increased secretion of TGFA protein]	12077271
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of TGFA mRNA	24449571
C526219	apple polyphenol extract	apple polyphenol extract results in increased expression of TGFA mRNA	18351577
D001151	Arsenic	[Arsenic co-treated with Fluorides] results in decreased expression of TGFA mRNA	19962721
D001151	Arsenic	Arsenic results in decreased expression of TGFA mRNA	19962721
D001151	Arsenic	Arsenic results in increased expression of TGFA mRNA	19945496
D001151	Arsenic	Arsenic results in increased expression of TGFA protein	17056473
D000077237	Arsenic Trioxide	TGFA protein results in decreased susceptibility to Arsenic Trioxide	20707922
C015001	arsenite	arsenite results in increased expression of TGFA mRNA	25257954
C015001	arsenite	arsenite results in increased expression of TGFA protein	25257954
C015001	arsenite	arsenite results in increased methylation of TGFA promoter	23974009
D001241	Aspirin	[Aspirin co-treated with Hydrochloric Acid] results in increased expression of TGFA mRNA	9726391
D001241	Aspirin	Aspirin results in decreased expression of TGFA mRNA	12231391
D001280	Atrazine	Atrazine affects the methylation of TGFA gene	28931070
C080985	batimastat	batimastat inhibits the reaction [TAC1 protein results in increased secretion of TGFA protein]	15319441
C080985	batimastat	batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of TGFA protein]	27117977
C080985	batimastat	batimastat results in decreased secretion of TGFA protein	27117977
C026487	benzo(e)pyrene	benzo(e)pyrene results in decreased methylation of TGFA intron	30157460
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of TGFA mRNA	30951980
C006780	bisphenol A	bisphenol A results in decreased methylation of TGFA intron	30906313
C006780	bisphenol A	bisphenol A affects the expression of TGFA mRNA	20170705
C006780	bisphenol A	bisphenol A results in increased expression of TGFA mRNA	19371625; 23019147; 31230753;
C006780	bisphenol A	[ADAM17 protein co-treated with ADAM10 protein] affects the reaction [bisphenol A results in increased secretion of TGFA protein]	28703301
C006780	bisphenol A	bisphenol A results in decreased expression of TGFA mRNA	26063408
C006780	bisphenol A	bisphenol A results in increased secretion of TGFA protein	28703301
C006780	bisphenol A	GW280264X inhibits the reaction [bisphenol A results in increased secretion of TGFA protein]	28703301
C006780	bisphenol A	bisphenol A affects the expression of TGFA mRNA	25181051
C006780	bisphenol A	[bisphenol A co-treated with tributyltin] results in increased expression of TGFA mRNA	31129395
D001971	Bromocriptine	Bromocriptine inhibits the reaction [Estradiol results in increased expression of TGFA mRNA]	1534540
D002084	Butylated Hydroxytoluene	Butylated Hydroxytoluene results in decreased susceptibility to TGFA protein	7593635
C018475	butyraldehyde	butyraldehyde results in increased expression of TGFA mRNA	26079696
D002101	Cacodylic Acid	Cacodylic Acid results in increased expression of TGFA mRNA	17720352
D002117	Calcitriol	Calcitriol results in increased expression of TGFA mRNA	16002434
D002118	Calcium	TGFA protein results in increased abundance of Calcium	11527950
D002118	Calcium	TGFA protein inhibits the reaction [Neomycin results in decreased abundance of Calcium]	9263032
D002118	Calcium	TGFA protein results in increased abundance of Calcium	9263032
D002211	Capsaicin	Capsaicin results in increased expression of TGFA mRNA	11989832
D002211	Capsaicin	Capsaicin results in increased expression of TGFA protein	11989832
D002251	Carbon Tetrachloride	Carbon Tetrachloride affects the expression of TGFA mRNA	17484886
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of TGFA mRNA	17468546
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased activity of TGFA protein	25858767
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of TGFA mRNA	17631135; 8847708;
D002392	Catechin	[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of TGFA mRNA	24763279
D000068579	Celecoxib	Celecoxib promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein]	15309881
D004390	Chlorpyrifos	Chlorpyrifos results in increased expression of TGFA mRNA	20350560
D002762	Cholecalciferol	[Hexachlorobenzene co-treated with Diethylnitrosamine co-treated with Cholecalciferol] results in increased expression of TGFA protein	28634113
D002945	Cisplatin	Cisplatin results in increased expression of TGFA mRNA	27392435; 27594783;
D002945	Cisplatin	TGFA protein results in decreased susceptibility to Cisplatin	16734730
D003314	Corn Oil	Corn Oil results in decreased expression of TGFA mRNA	22760963
D000077547	Crizotinib	EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to Crizotinib]	22553343
D000077547	Crizotinib	Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to Crizotinib]	22553343
D000077547	Crizotinib	TGFA protein inhibits the reaction [Crizotinib results in decreased phosphorylation of AKT1 protein]	22553343
D000077547	Crizotinib	TGFA protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK1 protein]	22553343
D000077547	Crizotinib	TGFA protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]	22553343
D000077547	Crizotinib	TGFA protein results in decreased susceptibility to Crizotinib	22553343
D003471	Cuprizone	Cuprizone results in decreased expression of TGFA mRNA	26577399; 27523638;
D003513	Cycloheximide	Cycloheximide results in increased expression of TGFA mRNA	15228094
C093628	cyproconazole	cyproconazole results in increased expression of TGFA mRNA	22334560
C515055	darinaparsin	darinaparsin results in decreased expression of TGFA mRNA	22535156
D000077209	Decitabine	Decitabine results in increased expression of TGFA mRNA	27915011
D003907	Dexamethasone	Dexamethasone inhibits the reaction [Antigens, Dermatophagoides results in increased secretion of TGFA protein]	12077271
D003915	Dextromethorphan	Dextromethorphan inhibits the reaction [Lipopolysaccharides results in increased secretion of TGFA]	15987631
D003931	Diacetyl	Diacetyl results in increased secretion of TGFA protein	30851105
D003980	Diazooxonorleucine	Diazooxonorleucine inhibits the reaction [Glucose results in increased expression of TGFA mRNA]	8638660
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of TGFA mRNA	21266533
D004008	Diclofenac	Diclofenac results in increased expression of TGFA mRNA	19022234
D004041	Dietary Fats	Dietary Fats results in increased expression of TGFA mRNA	25016146
D004052	Diethylnitrosamine	BCL2 protein inhibits the reaction [TGFA protein results in increased susceptibility to Diethylnitrosamine]	12000706
D004052	Diethylnitrosamine	[Hexachlorobenzene co-treated with Diethylnitrosamine co-treated with Cholecalciferol] results in increased expression of TGFA protein	28634113
D004052	Diethylnitrosamine	[Hexachlorobenzene co-treated with Diethylnitrosamine] results in increased expression of TGFA protein	28634113
D004052	Diethylnitrosamine	TGFA protein results in increased susceptibility to Diethylnitrosamine	12000706
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of TGFA mRNA	15660382; 18665156;
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of TGFA protein	18367157
D004052	Diethylnitrosamine	Plant Extracts inhibits the reaction [Diethylnitrosamine results in increased expression of TGFA protein]	18367157
D004052	Diethylnitrosamine	TGFA affects the susceptibility to Diethylnitrosamine	7923571
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of TGFA mRNA	19371625
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of TGFA mRNA	15336711
D004177	Dipyrone	Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein]	15309881
D016291	Dizocilpine Maleate	Dizocilpine Maleate inhibits the reaction [Lipopolysaccharides results in increased secretion of TGFA]	15987631
D004317	Doxorubicin	Doxorubicin results in increased expression of TGFA mRNA	30031762
C109476	epoxiconazole	epoxiconazole results in increased expression of TGFA mRNA	22334560
D000069347	Erlotinib Hydrochloride	Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to Crizotinib]	22553343
C472787	erucylphospho-N,N,N-trimethylpropylammonium	erucylphospho-N,N,N-trimethylpropylammonium results in increased expression of TGFA mRNA	29464035
D004958	Estradiol	Estradiol affects the expression of TGFA mRNA	14699072
D004958	Estradiol	[Estradiol co-treated with EGF protein] results in increased expression of TGFA mRNA	24758408
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in decreased expression of TGFA mRNA	20660070
D004958	Estradiol	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of TGFA mRNA	19619570
D004958	Estradiol	Estradiol results in increased expression of TGFA mRNA	11813992; 15120416; 17555868; 19619570; 20540524; 23019147; 24758408;
D004958	Estradiol	Fulvestrant inhibits the reaction [Estradiol results in increased expression of TGFA mRNA]	20540524
D004958	Estradiol	Tamoxifen inhibits the reaction [[Estradiol co-treated with EGF protein] results in increased expression of TGFA mRNA]	24758408
D004958	Estradiol	Tamoxifen inhibits the reaction [Estradiol results in increased expression of TGFA mRNA]	24758408
D004958	Estradiol	Estradiol inhibits the reaction [manganese chloride results in decreased expression of TGFA protein]	29183790
D004958	Estradiol	Bromocriptine inhibits the reaction [Estradiol results in increased expression of TGFA mRNA]	1534540
D004958	Estradiol	Estradiol results in increased expression of TGFA mRNA	11498938; 1534540;
D004958	Estradiol	Estradiol results in increased expression of TGFA mRNA	12594813
D000431	Ethanol	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of TGFA mRNA	26865667
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of TGFA mRNA	18936297
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of TGFA mRNA	17942748
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of TGFA mRNA	23550701
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of TGFA mRNA	23129252
D005047	Etoposide	Etoposide results in increased expression of TGFA mRNA	15228094
C574336	excavatolide B	excavatolide B results in decreased expression of TGFA protein	26790859
D017313	Fenretinide	Fenretinide results in increased expression of TGFA mRNA	28973697
C020326	ferric nitrilotriacetate	ferric nitrilotriacetate results in increased expression of TGFA mRNA	8340253
C020326	ferric nitrilotriacetate	ferric nitrilotriacetate results in increased expression of TGFA protein	8340253
D005459	Fluorides	[Arsenic co-treated with Fluorides] results in decreased expression of TGFA mRNA	19962721
D005459	Fluorides	Fluorides results in decreased expression of TGFA mRNA	19962721
D005472	Fluorouracil	TP53 protein affects the reaction [Fluorouracil results in increased expression of TGFA mRNA]	15016801
D005557	Formaldehyde	Formaldehyde results in decreased expression of TGFA mRNA	28937961
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [4-hydroxy-equilenin results in increased expression of TGFA mRNA]	20540524
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [Estradiol results in increased expression of TGFA mRNA]	20540524
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [Resveratrol results in increased expression of TGFA mRNA]	12594813
D005665	Furosemide	Furosemide results in increased expression of TGFA mRNA	16526316
D005742	Gasoline	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D005742	Gasoline	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D005742	Gasoline	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D005742	Gasoline	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D000077156	Gefitinib	5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]	21266357
D000077156	Gefitinib	Gefitinib inhibits the reaction [Irinotecan metabolite results in increased secretion of TGFA protein]	15723263
D000077156	Gefitinib	Gefitinib inhibits the reaction [Irinotecan results in increased secretion of TGFA protein]	15723263
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]	21266357
D000077156	Gefitinib	TGFA protein results in decreased susceptibility to Gefitinib	16230376
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]	18424623
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]	18424623
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]	18424623
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]	18424623
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]	18424623
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]	18424623
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]	18424623
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]	18424623
D019833	Genistein	Genistein inhibits the reaction [TGFA protein results in increased expression of PTGS2 mRNA]	10783318
D019833	Genistein	Genistein results in increased expression of TGFA mRNA	19371625; 23019147; 26865667;
D019833	Genistein	[Genistein co-treated with vinclozolin] affects the expression of TGFA mRNA	23410115
D019833	Genistein	[Genistein co-treated with vinclozolin] results in decreased expression of TGFA mRNA	22317923
D019833	Genistein	Genistein results in decreased expression of TGFA mRNA	23410115
D005944	Glucosamine	Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA]	1518840
D005944	Glucosamine	[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein	1518840
D005947	Glucose	Diazooxonorleucine inhibits the reaction [Glucose results in increased expression of TGFA mRNA]	8638660
D005947	Glucose	EGF protein promotes the reaction [Glucose results in increased expression of TGFA mRNA]	8638660
D005947	Glucose	Glucose promotes the reaction [EGF protein results in increased expression of TGFA mRNA]	8638660
D005947	Glucose	Glucose results in increased expression of TGFA mRNA	8638660
D005947	Glucose	Glucosamine promotes the reaction [Glucose results in increased expression of TGFA mRNA]	1518840
D005947	Glucose	[Glucose co-treated with Glucosamine] results in increased expression of TGFA protein	1518840
D005947	Glucose	Glucose results in increased expression of TGFA mRNA	1518840
C511402	Grape Seed Proanthocyanidins	[Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of TGFA mRNA	24763279
C492546	GW280264X	GW280264X inhibits the reaction [4-nonylphenol results in increased secretion of TGFA protein]	28703301
C492546	GW280264X	GW280264X inhibits the reaction [bisphenol A results in increased secretion of TGFA protein]	28703301
C492546	GW280264X	GW280264X inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TGFA protein]	28703301
D006581	Hexachlorobenzene	[Hexachlorobenzene co-treated with Diethylnitrosamine co-treated with Cholecalciferol] results in increased expression of TGFA protein	28634113
D006581	Hexachlorobenzene	[Hexachlorobenzene co-treated with Diethylnitrosamine] results in increased expression of TGFA protein	28634113
D006851	Hydrochloric Acid	[Aspirin co-treated with Hydrochloric Acid] results in increased expression of TGFA mRNA	9726391
D006851	Hydrochloric Acid	Celecoxib promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein]	15309881
D006851	Hydrochloric Acid	Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein]	15309881
D006851	Hydrochloric Acid	Hydrochloric Acid results in increased expression of TGFA protein	15309881
D006851	Hydrochloric Acid	Piroxicam promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein]	15309881
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TGFA mRNA	25613284
D000077146	Irinotecan	Gefitinib inhibits the reaction [Irinotecan metabolite results in increased secretion of TGFA protein]	15723263
D000077146	Irinotecan	Gefitinib inhibits the reaction [Irinotecan results in increased secretion of TGFA protein]	15723263
D000077146	Irinotecan	Irinotecan metabolite results in increased secretion of TGFA protein	15723263
D000077146	Irinotecan	Irinotecan results in increased secretion of TGFA protein	15723263
D000077146	Irinotecan	rottlerin inhibits the reaction [Irinotecan metabolite results in increased secretion of TGFA protein]	15723263
D000077146	Irinotecan	rottlerin inhibits the reaction [Irinotecan results in increased secretion of TGFA protein]	15723263
D000077146	Irinotecan	TGFA protein results in decreased susceptibility to Irinotecan	16734730
C040507	isobutyl alcohol	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
C561695	(+)-JQ1 compound	[(+)-JQ1 compound co-treated with Vemurafenib] results in decreased expression of TGFA mRNA	27169980
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of TGFA mRNA	25961927
C006552	kaempferol	kaempferol inhibits the reaction [TGFA protein results in increased expression of PTGS2 mRNA]	10783318
C107086	KB R7785	KB R7785 inhibits the reaction [CXCL8 protein results in increased cleavage of and results in increased secretion of TGFA protein]	15300588
D019344	Lactic Acid	Lactic Acid results in decreased expression of TGFA mRNA	30851411
D064747	Lansoprazole	Lansoprazole results in increased expression of TGFA protein	9881512
D000077339	Leflunomide	Leflunomide results in increased expression of TGFA mRNA	28988120
C038753	leptomycin B	acteoside inhibits the reaction [leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]]	21967610
C038753	leptomycin B	acteoside inhibits the reaction [leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]]	21967610
C038753	leptomycin B	[leptomycin B co-treated with TGFA protein co-treated with acteoside] affects the localization of EGFR protein modified form	21967610
C038753	leptomycin B	[leptomycin B co-treated with TGFA protein co-treated with polydatin] affects the localization of EGFR protein modified form	21967610
C038753	leptomycin B	[leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein	21967610
C038753	leptomycin B	[leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein modified form	21967610
C038753	leptomycin B	[leptomycin B co-treated with TGFA protein co-treated with Resveratrol] affects the localization of EGFR protein modified form	21967610
C038753	leptomycin B	[leptomycin B co-treated with TGFA protein co-treated with Rutin] affects the localization of EGFR protein modified form	21967610
C038753	leptomycin B	leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]	21967610
C038753	leptomycin B	leptomycin B promotes the reaction [TGFA protein affects the localization of EGFR protein]	21967610
C038753	leptomycin B	leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]	21967610
C038753	leptomycin B	Quercetin inhibits the reaction [leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]]	21967610
C038753	leptomycin B	Quercetin inhibits the reaction [leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]]	21967610
C038753	leptomycin B	Resveratrol inhibits the reaction [leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]]	21967610
C038753	leptomycin B	Resveratrol inhibits the reaction [leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]]	21967610
C038753	leptomycin B	Rutin inhibits the reaction [leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]]	21967610
C038753	leptomycin B	Rutin inhibits the reaction [leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]]	21967610
C533894	LG 100815	LG 100815 results in increased expression of TGFA mRNA	16951191
D008012	Lidocaine	Lidocaine results in decreased expression of TGFA protein	18382663
D000077222	Limonene	Limonene results in increased expression of TGFA mRNA	12815608
D008070	Lipopolysaccharides	Dextromethorphan inhibits the reaction [Lipopolysaccharides results in increased secretion of TGFA]	15987631
D008070	Lipopolysaccharides	Dizocilpine Maleate inhibits the reaction [Lipopolysaccharides results in increased secretion of TGFA]	15987631
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased secretion of TGFA	15987631
D000077276	Lycopene	Lycopene results in increased expression of TGFA mRNA	16886892
D008345	Manganese	Manganese results in increased expression of TGFA mRNA	18284614
C025340	manganese chloride	Estradiol inhibits the reaction [manganese chloride results in decreased expression of TGFA protein]	29183790
C025340	manganese chloride	manganese chloride results in decreased expression of TGFA protein	29183790
C025340	manganese chloride	Tamoxifen inhibits the reaction [manganese chloride results in decreased expression of TGFA protein]	29183790
C100342	marimastat	marimastat inhibits the reaction [GRP protein results in increased cleavage of and results in increased secretion of TGFA protein]	15342401
D008555	Melitten	Melitten results in increased secretion of TGFA protein	22613720
D008627	Mercuric Chloride	Mercuric Chloride results in increased expression of TGFA mRNA	10901180
D008627	Mercuric Chloride	Mercuric Chloride results in increased expression of TGFA protein	10901180
D008701	Methapyrilene	Methapyrilene results in decreased methylation of TGFA intron	30157460
D008727	Methotrexate	Methotrexate results in decreased expression of TGFA mRNA	24449571
D008727	Methotrexate	Methotrexate results in increased expression of TGFA mRNA	21678067
D008727	Methotrexate	TGFA protein inhibits the reaction [Methotrexate results in decreased expression of BCL2 mRNA]	18803016
D008727	Methotrexate	TGFA protein inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]	18803016
D008727	Methotrexate	TGFA protein inhibits the reaction [Methotrexate results in increased expression of BAX mRNA]	18803016
D008727	Methotrexate	TGFA protein inhibits the reaction [Methotrexate results in increased expression of BAX protein]	18803016
D015735	Mifepristone	Mifepristone results in decreased expression of TGFA mRNA	18591650
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of TGFA mRNA	20886546
D009151	Mustard Gas	Mustard Gas results in increased expression of TGFA mRNA	18955075
C092152	N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide	N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [ELANE protein results in increased expression of TGFA protein]	17456367
C092152	N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide	N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [Silicon Dioxide analog results in increased secretion of TGFA protein]	24844442
C078131	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
C078131	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D009355	Neomycin	TGFA protein inhibits the reaction [Neomycin results in decreased abundance of Calcium]	9263032
C029938	nickel sulfate	TGFA protein affects the susceptibility to nickel sulfate	19131640
C029938	nickel sulfate	[TGFA protein binds to and affects the activity of EGFR protein] which results in decreased susceptibility to nickel sulfate	19131640
C029938	nickel sulfate	TGFA protein inhibits the reaction [nickel sulfate results in decreased expression of SFTPB protein]	11954676
D009538	Nicotine	Nicotine results in increased secretion of TGFA protein	17630920
D009583	Nitrofurazone	Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of TGFA mRNA]	15945272
D009583	Nitrofurazone	Nitrofurazone results in increased expression of TGFA mRNA	15945272
C014707	nitrosobenzylmethylamine	nitrosobenzylmethylamine results in increased expression of TGFA mRNA	17616710
C516714	NVP-TAE684	TGFA protein results in decreased susceptibility to NVP-TAE684	22553343
C062198	octa-2,4,6-trienoic acid	octa-2,4,6-trienoic acid results in increased expression of TGFA mRNA	16951191
C016340	o,p'-DDT	o,p'-DDT results in increased expression of TGFA mRNA	19371625
D010100	Oxygen	Oxygen deficiency results in increased expression of TGFA mRNA	11171960
D010100	Oxygen	Oxygen deficiency results in increased expression of TGFA protein	11171960
D010126	Ozone	Ozone results in increased expression of TGFA protein	26464147
D010269	Paraquat	Paraquat affects the expression of TGFA mRNA	15206577; 16854511;
D052638	Particulate Matter	AR protein affects the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
D052638	Particulate Matter	[AR protein co-treated with TGFA protein co-treated with HBEGF protein] affects the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
D052638	Particulate Matter	EGFR protein affects the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
D052638	Particulate Matter	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D052638	Particulate Matter	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D052638	Particulate Matter	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D052638	Particulate Matter	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D052638	Particulate Matter	HBEGF protein affects the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
D052638	Particulate Matter	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
D052638	Particulate Matter	Particulate Matter results in increased expression of TGFA mRNA	24555532
D052638	Particulate Matter	Particulate Matter results in increased secretion of TGFA protein	22820758; 24555532;
D052638	Particulate Matter	RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
D052638	Particulate Matter	TGFA protein affects the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
D052638	Particulate Matter	Particulate Matter results in increased expression of TGFA mRNA	22820758
C410127	PCB 180	[2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of TGFA mRNA	21277884
C509204	PD168393	PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]	21967610
C509204	PD168393	PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]	21967610
C509204	PD168393	PD168393 inhibits the reaction [[TGFA protein co-treated with acteoside] results in increased expression of CXCL8 mRNA]	21967610
C509204	PD168393	PD168393 inhibits the reaction [[TGFA protein co-treated with polydatin] results in increased expression of CXCL8 mRNA]	21967610
C509204	PD168393	PD168393 inhibits the reaction [[TGFA protein co-treated with polydatin] results in increased secretion of CXCL8 protein]	21967610
C509204	PD168393	PD168393 inhibits the reaction [[TGFA protein co-treated with Quercetin] results in increased expression of CXCL8 mRNA]	21967610
C509204	PD168393	PD168393 inhibits the reaction [[TGFA protein co-treated with Resveratrol] results in increased expression of CXCL8 mRNA]	21967610
C509204	PD168393	PD168393 inhibits the reaction [[TGFA protein co-treated with Resveratrol] results in increased secretion of CXCL8 protein]	21967610
C509204	PD168393	PD168393 inhibits the reaction [TGFA protein results in increased expression of CXCL8 mRNA]	21967610
C509204	PD168393	PD168393 inhibits the reaction [TGFA protein results in increased secretion of CXCL8 protein]	21967610
C509204	PD168393	PD168393 promotes the reaction [TGFA protein results in increased expression of CCL2 mRNA]	21967610
C509204	PD168393	PD168393 promotes the reaction [TGFA protein results in increased expression of CXCL10 mRNA]	21967610
C509204	PD168393	[PD168393 results in decreased activity of EGFR protein] which results in decreased susceptibility to TGFA protein	21967610
D010634	Phenobarbital	TGFA affects the susceptibility to Phenobarbital	7923571
D010672	Phenytoin	Phenytoin results in increased expression of TGFA mRNA	9988880
C018637	phorone	phorone affects the expression of TGFA mRNA	18198479
C121565	pifithrin	pifithrin results in decreased expression of TGFA protein	12143041
C121565	pifithrin	TP53 protein affects the reaction [pifithrin results in decreased expression of TGFA protein]	12143041
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of TGFA mRNA	19710929
C006253	pirinixic acid	pirinixic acid results in increased expression of TGFA mRNA	23811191
C006253	pirinixic acid	pirinixic acid results in increased expression of TGFA mRNA	19162173
D010894	Piroxicam	Piroxicam promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein]	15309881
D010936	Plant Extracts	Plant Extracts results in increased expression of TGFA mRNA	18351577
D010936	Plant Extracts	Plant Extracts inhibits the reaction [Diethylnitrosamine results in increased expression of TGFA protein]	18367157
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with 1-Butanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with Ethanol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[[Gasoline co-treated with isobutyl alcohol] results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
D011084	Polycyclic Aromatic Hydrocarbons	[Gasoline results in increased chemical synthesis of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TGFA mRNA	29432896
C058229	polydatin	[polydatin co-treated with TGFA protein] results in increased expression of CXCL10 mRNA	21756928
C058229	polydatin	[polydatin co-treated with TGFA protein] results in increased expression of CXCL8 mRNA	21756928
C058229	polydatin	polydatin inhibits the reaction [TGFA protein affects the localization of EGFR protein]	21967610
C058229	polydatin	[leptomycin B co-treated with TGFA protein co-treated with polydatin] affects the localization of EGFR protein modified form	21967610
C058229	polydatin	PD168393 inhibits the reaction [[TGFA protein co-treated with polydatin] results in increased expression of CXCL8 mRNA]	21967610
C058229	polydatin	PD168393 inhibits the reaction [[TGFA protein co-treated with polydatin] results in increased secretion of CXCL8 protein]	21967610
C058229	polydatin	polydatin inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]	21967610
C058229	polydatin	polydatin promotes the reaction [[TGFA protein co-treated with IFNG protein] results in increased expression of and results in increased secretion of CXCL8 protein]	21967610
C058229	polydatin	polydatin promotes the reaction [[TGFA protein co-treated with IFNG protein] results in increased expression of CXCL8 mRNA]	21967610
C058229	polydatin	polydatin promotes the reaction [TGFA protein results in increased expression of CXCL8 mRNA]	21967610
C058229	polydatin	polydatin promotes the reaction [TGFA protein results in increased expression of CXCL8 protein]	21967610
C058229	polydatin	[TGFA protein co-treated with polydatin] results in increased expression of CXCL8 mRNA	21967610
C058229	polydatin	[TGFA protein co-treated with polydatin] results in increased secretion of CXCL8 protein	21967610
C443641	poly(propyleneimine)	poly(propyleneimine) analog results in increased expression of TGFA mRNA	16308212
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in decreased expression of TGFA mRNA	20660070
D011374	Progesterone	Progesterone results in increased expression of TGFA mRNA	18591650
C045950	propiconazole	propiconazole results in increased expression of TGFA mRNA	22334560
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of TGFA mRNA	25825206
C024631	pyrvinium	pyrvinium inhibits the reaction [PIK3CA protein modified form results in decreased expression of TGFA mRNA]	27542212
D011794	Quercetin	[Quercetin co-treated with TGFA protein] results in increased expression of CXCL8 mRNA	21756928
D011794	Quercetin	[Quercetin co-treated with TGFA protein] results in increased expression of TNF mRNA	21756928
D011794	Quercetin	Quercetin inhibits the reaction [TGFA protein results in increased expression of PTGS2 mRNA]	10783318
D011794	Quercetin	Quercetin inhibits the reaction [TGFA protein results in increased phosphorylation of AKT1 protein]	12888923
D011794	Quercetin	Quercetin inhibits the reaction [TGFA protein results in increased phosphorylation of ELK1 protein]	12888923
D011794	Quercetin	Quercetin inhibits the reaction [TGFA protein results in increased phosphorylation of ERBB2 protein]	12888923
D011794	Quercetin	Quercetin inhibits the reaction [TGFA protein results in increased phosphorylation of ERBB3 protein]	12888923
D011794	Quercetin	Quercetin inhibits the reaction [TGFA protein results in increased phosphorylation of RAF1 protein]	12888923
D011794	Quercetin	[leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein	21967610
D011794	Quercetin	[leptomycin B co-treated with TGFA protein co-treated with Quercetin] affects the localization of EGFR protein modified form	21967610
D011794	Quercetin	PD168393 inhibits the reaction [[TGFA protein co-treated with Quercetin] results in increased expression of CXCL8 mRNA]	21967610
D011794	Quercetin	Quercetin inhibits the reaction [leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]]	21967610
D011794	Quercetin	Quercetin inhibits the reaction [leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]]	21967610
D011794	Quercetin	Quercetin inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of EGFR protein]	21967610
D011794	Quercetin	Quercetin inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]	21967610
D011794	Quercetin	Quercetin inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein]	21967610
D011794	Quercetin	Quercetin promotes the reaction [TGFA protein affects the localization of EGFR protein]	21967610
D011794	Quercetin	Quercetin promotes the reaction [TGFA protein affects the localization of EGFR protein modified form]	21967610
D011794	Quercetin	Quercetin results in increased susceptibility to TGFA protein	21967610
D011794	Quercetin	[TGFA protein co-treated with Quercetin] results in increased expression of CXCL8 mRNA	21967610
C005266	quinomethionate	quinomethionate affects the expression of TGFA mRNA	15387888
D020849	Raloxifene Hydrochloride	[Raloxifene Hydrochloride co-treated with ESR2 protein] results in decreased expression of TGFA mRNA	19059307
C031389	resorcinol	resorcinol inhibits the reaction [TGFA protein results in increased expression of PTGS2 mRNA]	10783318
D000077185	Resveratrol	[Resveratrol co-treated with TGFA protein] results in increased expression of CXCL8 mRNA	21756928
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFA protein affects the localization of EGFR protein]	21967610
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFA protein results in increased expression of PTGS2 mRNA]	10783318
D000077185	Resveratrol	Resveratrol results in increased expression of TGFA mRNA	15120416
D000077185	Resveratrol	Fulvestrant inhibits the reaction [Resveratrol results in increased expression of TGFA mRNA]	12594813
D000077185	Resveratrol	[leptomycin B co-treated with TGFA protein co-treated with Resveratrol] affects the localization of EGFR protein modified form	21967610
D000077185	Resveratrol	PD168393 inhibits the reaction [[TGFA protein co-treated with Resveratrol] results in increased expression of CXCL8 mRNA]	21967610
D000077185	Resveratrol	PD168393 inhibits the reaction [[TGFA protein co-treated with Resveratrol] results in increased secretion of CXCL8 protein]	21967610
D000077185	Resveratrol	Resveratrol inhibits the reaction [leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]]	21967610
D000077185	Resveratrol	Resveratrol inhibits the reaction [leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]]	21967610
D000077185	Resveratrol	Resveratrol inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]	21967610
D000077185	Resveratrol	Resveratrol promotes the reaction [[TGFA protein co-treated with IFNG protein] results in increased expression of and results in increased secretion of CXCL8 protein]	21967610
D000077185	Resveratrol	Resveratrol promotes the reaction [[TGFA protein co-treated with IFNG protein] results in increased expression of CXCL8 mRNA]	21967610
D000077185	Resveratrol	Resveratrol promotes the reaction [TGFA protein results in increased expression of CXCL8 mRNA]	21967610
D000077185	Resveratrol	Resveratrol promotes the reaction [TGFA protein results in increased expression of CXCL8 protein]	21967610
D000077185	Resveratrol	Resveratrol results in increased expression of TGFA mRNA	12594813
D000077185	Resveratrol	[TGFA protein co-treated with Resveratrol] results in increased expression of CXCL8 mRNA	21967610
D000077185	Resveratrol	[TGFA protein co-treated with Resveratrol] results in increased secretion of CXCL8 protein	21967610
C013672	riddelliine	riddelliine results in decreased expression of TGFA mRNA	18047727
C085746	rottlerin	rottlerin inhibits the reaction [Irinotecan metabolite results in increased secretion of TGFA protein]	15723263
C085746	rottlerin	rottlerin inhibits the reaction [Irinotecan results in increased secretion of TGFA protein]	15723263
C101044	RTKI cpd	RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of TGFA protein]	24555532
C101044	RTKI cpd	RTKI cpd inhibits the reaction [TGFA protein results in increased expression of FOS protein]	19749156
C101044	RTKI cpd	RTKI cpd inhibits the reaction [TGFA protein results in increased expression of GPER1 protein]	19749156
C101044	RTKI cpd	RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of AKT1 protein]	11309286
C101044	RTKI cpd	RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]	11309286
C101044	RTKI cpd	RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]	11309286
C101044	RTKI cpd	RTKI cpd inhibits the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D012431	Rutin	Rutin inhibits the reaction [TGFA protein affects the localization of EGFR protein]	21967610
D012431	Rutin	[leptomycin B co-treated with TGFA protein co-treated with Rutin] affects the localization of EGFR protein modified form	21967610
D012431	Rutin	Rutin inhibits the reaction [leptomycin B inhibits the reaction [TGFA protein results in decreased secretion of CCL2 protein]]	21967610
D012431	Rutin	Rutin inhibits the reaction [leptomycin B promotes the reaction [TGFA protein results in increased secretion of CXCL8 protein]]	21967610
D012431	Rutin	Rutin inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased phosphorylation of RELA protein]	21967610
D012431	Rutin	Rutin inhibits the reaction [[TGFA protein co-treated with IFNG protein] results in increased secretion of CXCL8 protein]	21967610
D012431	Rutin	Rutin promotes the reaction [TGFA protein results in increased phosphorylation of EGFR protein]	21967610
C410733	scriptaid	scriptaid affects the expression of TGFA mRNA	18813790
D012822	Silicon Dioxide	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Silicon Dioxide analog results in increased secretion of TGFA protein]	24844442
D012822	Silicon Dioxide	N-((2-(hydroxyaminocarbonyl)methyl)-4-methylpentanoyl)-3-(2'-naphthyl)alanylalanine, 2-aminoethylamide inhibits the reaction [Silicon Dioxide analog results in increased secretion of TGFA protein]	24844442
D012822	Silicon Dioxide	Silicon Dioxide analog results in increased expression of TGFA mRNA	25895662
D012822	Silicon Dioxide	Silicon Dioxide analog results in increased secretion of TGFA protein	24844442
D012906	Smoke	Smoke results in decreased nitrosation of TGFA protein	21652289
C017947	sodium arsenite	sodium arsenite affects the methylation of TGFA gene	28589171
C017947	sodium arsenite	sodium arsenite results in increased expression of and results in increased stability of TGFA mRNA	8917704
C017947	sodium arsenite	sodium arsenite results in increased expression of TGFA mRNA	20886546; 9219559;
C017947	sodium arsenite	sodium arsenite results in increased expression of TGFA protein	30137596
C017947	sodium arsenite	sodium arsenite results in increased secretion of TGFA protein	8917704; 9219559;
C017947	sodium arsenite	TGFA protein promotes the reaction [sodium arsenite results in increased phosphorylation of ERBB2 protein]	30137596
C017947	sodium arsenite	sodium arsenite results in increased expression of TGFA mRNA	9846968
C017947	sodium arsenite	sodium arsenite results in increased expression of TGFA protein	9846968
D000077210	Sunitinib	Sunitinib results in increased expression of TGFA mRNA	31533062
D013629	Tamoxifen	Tamoxifen affects the expression of TGFA mRNA	14699072
D013629	Tamoxifen	[Tamoxifen co-treated with ESR2 protein] results in decreased expression of TGFA mRNA	19059307
D013629	Tamoxifen	Tamoxifen inhibits the reaction [[Estradiol co-treated with EGF protein] results in increased expression of TGFA mRNA]	24758408
D013629	Tamoxifen	Tamoxifen inhibits the reaction [Estradiol results in increased expression of TGFA mRNA]	24758408
D013629	Tamoxifen	Tamoxifen inhibits the reaction [manganese chloride results in decreased expression of TGFA protein]	29183790
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in increased expression of TGFA mRNA	15336504
D013749	Tetrachlorodibenzodioxin	3'-methoxy-4'-nitroflavone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TGFA mRNA]	12668121
D013749	Tetrachlorodibenzodioxin	[AREG protein co-treated with EREG protein co-treated with TGFA protein] affects the reaction [Tetrachlorodibenzodioxin results in increased activity of MAPK1 protein]	27117977
D013749	Tetrachlorodibenzodioxin	[AREG protein co-treated with EREG protein co-treated with TGFA protein] affects the reaction [Tetrachlorodibenzodioxin results in increased activity of MAPK3 protein]	27117977
D013749	Tetrachlorodibenzodioxin	batimastat inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of TGFA protein]	27117977
D013749	Tetrachlorodibenzodioxin	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of TGFA mRNA	19619570
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TGFA mRNA	11309286; 11489354; 12668121; 1447203; 17555868; 19619570; 2033054; 23152189; 7755487; 9163677; 9787404;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TGFA protein	11309286; 12668121; 9787404;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased secretion of TGFA protein	2033054; 27117977; 9163677;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased stability of TGFA mRNA	1447203
D013749	Tetrachlorodibenzodioxin	SRC protein promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TGFA mRNA]	14708085
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of TGFA mRNA	12167310
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of TGFA mRNA	19933214
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of TGFA protein	2260090
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TGFA mRNA	14708085; 15667827;
D013749	Tetrachlorodibenzodioxin	TGFA gene mutant form affects the susceptibility to Tetrachlorodibenzodioxin	11399798
D013749	Tetrachlorodibenzodioxin	TGFA gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PCK1 mRNA]	16906519
D013749	Tetrachlorodibenzodioxin	TGFA gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPB mRNA]	16906519
D013749	Tetrachlorodibenzodioxin	TGFA gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAPK1 mRNA]	16906519
D013749	Tetrachlorodibenzodioxin	TGFA gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SRC mRNA]	16906519
D013749	Tetrachlorodibenzodioxin	TGFA protein affects the susceptibility to Tetrachlorodibenzodioxin	16906519
D013749	Tetrachlorodibenzodioxin	[TGFA protein co-treated with EGF protein] affects the susceptibility to Tetrachlorodibenzodioxin	12520078
D013749	Tetrachlorodibenzodioxin	TGFA protein results in decreased susceptibility to Tetrachlorodibenzodioxin	14514962
D013749	Tetrachlorodibenzodioxin	Tretinoin promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of TGFA protein]	2260090
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased stability of TGFA mRNA	10833433
D013755	Tetradecanoylphorbol Acetate	ADAM17 protein affects the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TGFA protein]	28703301
D013755	Tetradecanoylphorbol Acetate	GW280264X inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TGFA protein]	28703301
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased cleavage of and results in increased secretion of TGFA protein	15066986
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate results in increased secretion of TGFA protein	28703301
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TGFA mRNA	25613284
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of TGFA mRNA	29505817; 30610935;
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of TGFA protein	29505817
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased secretion of TGFA protein	27404394
D014212	Tretinoin	Tretinoin results in increased expression of TGFA mRNA	21934132
D014212	Tretinoin	Tretinoin results in increased secretion of TGFA protein	16473924
D014212	Tretinoin	Tretinoin promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of TGFA protein]	2260090
D014212	Tretinoin	Tretinoin results in increased expression of TGFA mRNA	20488242
C011559	tributyltin	tributyltin results in decreased expression of TGFA mRNA	29505797
C011559	tributyltin	[bisphenol A co-treated with tributyltin] results in increased expression of TGFA mRNA	31129395
C012589	trichostatin A	trichostatin A results in increased expression of TGFA mRNA	24935251
D014260	Triclosan	Triclosan results in decreased expression of TGFA protein	30219713
D014260	Triclosan	Triclosan results in increased expression of TGFA protein	30219713
C015559	trimellitic anhydride	trimellitic anhydride results in decreased expression of TGFA mRNA	19042947
D000077288	Troglitazone	Troglitazone results in increased expression of TGFA mRNA	19022234
D014635	Valproic Acid	Valproic Acid results in increased expression of TGFA mRNA	23179753; 24935251; 28001369;
D014635	Valproic Acid	Valproic Acid results in increased expression of TGFA mRNA	10689198
D014638	Vanadates	Vanadates results in increased expression of TGFA mRNA	22714537
D001335	Vehicle Emissions	AR protein affects the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D001335	Vehicle Emissions	[AR protein co-treated with TGFA protein co-treated with HBEGF protein] affects the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D001335	Vehicle Emissions	EGFR protein affects the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D001335	Vehicle Emissions	HBEGF protein affects the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D001335	Vehicle Emissions	N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D001335	Vehicle Emissions	RTKI cpd inhibits the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D001335	Vehicle Emissions	TGFA protein affects the reaction [Vehicle Emissions results in increased secretion of TGFA protein]	24555532
D001335	Vehicle Emissions	Vehicle Emissions results in increased expression of TGFA mRNA	24555532
D001335	Vehicle Emissions	Vehicle Emissions results in increased secretion of TGFA protein	24555532
D000077484	Vemurafenib	[(+)-JQ1 compound co-treated with Vemurafenib] results in decreased expression of TGFA mRNA	27169980
C025643	vinclozolin	[Genistein co-treated with vinclozolin] affects the expression of TGFA mRNA	23410115
C025643	vinclozolin	[Genistein co-treated with vinclozolin] results in decreased expression of TGFA mRNA	22317923
C025643	vinclozolin	vinclozolin results in decreased expression of TGFA mRNA	23410115
D014801	Vitamin A	Vitamin A deficiency results in increased expression of TGFA mRNA	7519440
D015025	Zearalenone	Zearalenone results in increased expression of TGFA mRNA	19371625
D019287	Zinc Sulfate	Zinc Sulfate results in increased expression of TGFA mRNA	27504894

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0025	Alternative splicing
KW-1003	Cell membrane
KW-1015	Disulfide bond
KW-0245	EGF-like domain
KW-0325	Glycoprotein
KW-0339	Growth factor
KW-0449	Lipoprotein
KW-0472	Membrane
KW-0497	Mitogen
KW-0564	Palmitate
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0964	Secreted
KW-0732	Signal
KW-0812	Transmembrane
KW-1133	Transmembrane helix

Interpro

InterPro ID	InterPro Term
IPR013032	EGF-like_CS
IPR000742	EGF-like_dom

PROSITE

PROSITE ID	PROSITE Term
PS00022	EGF_1
PS01186	EGF_2
PS50026	EGF_3

Pfam

Pfam ID	Pfam Term

Gene: TGFA

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Identified variants/mutations related to cleft phenotype

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction